Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin
(CBDCA) as first line treatment in advenced non-small lung
cancer (NSCLC) patients: results of a prospective study in
nonrandomized and unselected population of 396 patient

a 2013

Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient

SKŘIČKOVÁ, Jana, Bohdan KADLEC, Ondřej VENCLÍČEK, Lenka JAKUBÍKOVÁ, Tereza JANÁSKOVÁ et. al.

Basic information

Original name

Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient

Authors

Edition

15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia, 2013

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30203 Respiratory systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.800

Organization unit

Faculty of Medicine

ISSN

Keywords in English

first-line treatment; NSCLC

Změněno: 28/2/2014 17:07, Soňa Böhmová

Abstract

V originále

In this group of 396 unselected patients with advanced NSCLC was the treatment with full NVBO and-CBDCA in first line more convenient and well tolerated with evidence of high antitumour activity. This combination was active in all groups patients according histology (mOS was 9,92 and mPFS was 7,4 months). Statistically significant better were the results in patients with PS 0+1.

Citovat

SKŘIČKOVÁ, Jana, Bohdan KADLEC, Ondřej VENCLÍČEK, Lenka JAKUBÍKOVÁ, Tereza JANÁSKOVÁ, Vítězslav KOLEK, Ivona GRYGÁRKOVÁ, Helena ČOUPKOVÁ, Jiří CHALUPA, Jiří BARTOŠ, Pavel REITERER and Milada ZEMANOVÁ. Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient. In 15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia. 2013. ISSN 1556-0864.

@proceedings{1136258,
   author = {Skřičková, Jana and Kadlec, Bohdan and Venclíček, Ondřej and Jakubíková, Lenka and Janásková, Tereza and Kolek, Vítězslav and Grygárková, Ivona and Čoupková, Helena and Chalupa, Jiří and Bartoš, Jiří and Reiterer, Pavel and Zemanová, Milada},
   booktitle = {15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia},
   keywords = {first-line treatment; NSCLC},
   language = {eng},
   title = {Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient},
   year = {2013}
}

TY  - CONF
ID  - 1136258
AU  - Skřičková, Jana - Kadlec, Bohdan - Venclíček, Ondřej - Jakubíková, Lenka - Janásková, Tereza - Kolek, Vítězslav - Grygárková, Ivona - Čoupková, Helena - Chalupa, Jiří - Bartoš, Jiří - Reiterer, Pavel - Zemanová, Milada
PY  - 2013
TI  - Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient
KW  - first-line treatment
KW  - NSCLC
N2  - In this group of 396 unselected patients with advanced NSCLC was the treatment with full NVBO and-CBDCA in first line more convenient and well tolerated with evidence of high antitumour activity. This combination was active in all groups patients according histology (mOS was 9,92 and mPFS was 7,4 months). Statistically significant better were the results in patients with PS 0+1.
ER  -

SKŘIČKOVÁ, Jana, Bohdan KADLEC, Ondřej VENCLÍČEK, Lenka JAKUBÍKOVÁ, Tereza JANÁSKOVÁ, Vítězslav KOLEK, Ivona GRYGÁRKOVÁ, Helena ČOUPKOVÁ, Jiří CHALUPA, Jiří BARTOŠ, Pavel REITERER and Milada ZEMANOVÁ. Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient. In \textit{15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia}. 2013. ISSN~1556-0864.

Detailed Information on Publication Record